Regression of human immunodeficiency virus-associated oral Kaposi sarcoma with combined antiretroviral therapy: A case report and literature review.

Franco, Juliana Bertoldi; Maureira Pena, Loreto José; Martins E Martins, Fabiana; de Oliveira, Marcio Augusto; Ortega, Karem L · Head Neck · 2019

case_report · Level V

Where this comes from

Abstract

Kaposi's sarcoma (KS) is the most prevalent malignant neoplasia in human immunodeficiency virus positive (HIV+) patients for which the primary mode of management was chemotherapy. We have presented the case of a newly diagnosed HIV+ male patient who was diagnosed with a pedunculated nodule in the anterior region of the hard palate, measuring 3.5 cm in diameter and with 2 months of evolution. Histopathological examination confirmed the clinical hypothesis of KS. Soon after the diagnosis, the patient started using combined antiretroviral therapy (Biovir and Kaletra), presenting a significant reduction of the lesion after 4 weeks. With 1.5 cm in diameter, the lesion was surgically removed. The patient was followed-up for 10 years without any recurrence. In antiretroviral-naive patients with a well-preserved immune system, the use of cART may be efficient in reducing the progression of the KS lesions, thus avoiding the use of chemotherapeutic agents.

Medical subject headings